Batten Disease (BD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
Batten Disease Competitive Analysis Report Overview
Batten disease is also known as neuronal ceroid lipofuscinosis (NCL) and refers to a cluster of hereditary nervous system disorders that typically manifest in childhood. The diverse forms of the disease are categorized based on the gene responsible for the disorder. Due to the varying gene mutations that can cause the disease, the severity of symptoms and their progression rates differ. Symptoms typically include progressive vision loss leading to blindness, seizures, movement disorders, and dementia.
| Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
The Batten Disease (BD) marketed and pipeline drugs market research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, pricing and reimbursement, and late-to-mid-stage pipeline products with Phase Transition Success Rate (PTSR), and Likelihood of Approval (LoA) for BD. The report also analyzes the clinical and commercial landscapes of Batten disease, as well as an assessment of deals, future market catalysts, key market players, and the future competitive environment.
| Key Mechanisms of Action (Pipeline) | · Enzyme Activators
· Protein and Peptide Activators · Receptor Agonists · Biological Factor Replacements · Protein and Peptide Inhibitors · Enzyme Inhibitors · Enzyme Replacement |
| Key Routes of Administration (Pipeline) | · Injection
· Oral · Topical |
| Key Molecule Types (Pipeline) | · Biologics
· Small Molecules · Oligonucleotides |
| Top Sponsors (Marketed and Pipeline Drugs) | · BioMarin Pharmaceutical Inc
· Amicus Therapeutics Inc · RegenxBio Inc · University of Texas Southwestern Medical Centre · New York Medical College |
| Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
BD Pipeline Drugs Market Segmentation by Mechanisms of Action
The drugs under development for BD are mostly enzyme activators or protein and peptide activators by mechanism of action. The other MoAs are receptor agonists, biological factor replacements, protein and peptide inhibitors, enzyme inhibitors, and enzyme replacement.
BD Pipeline Drugs Market Analysis by Mechanisms of Action, 2023 (%)
Buy Full Report to Know More about the MoA of BD Pipeline Drugs
BD Pipeline Drugs Market Segmentation by Routes of Administration
The drugs under development for BD are mostly oral therapies followed by injectables and topical drugs.
BD Pipeline Drugs Market Analysis by Routes of Administration, 2023 (%)
Buy Full Report to Know More about the RoA of BD Pipeline Drugs
BD Pipeline Drugs Market Segmentation by Molecule Types
Most pipeline drugs for Batten Disease are small molecules, followed by biologics and oligonucleotides.
BD Pipeline Drugs Market Analysis by Molecule Types, 2023 (%)
Buy the Full Report to Know More about the Molecule Types of BD Pipeline Drugs
BD Marketed and Pipeline Drugs Market – Competitive Landscape
Some of the top sponsors in the BD marketed and pipeline drugs market are BioMarin Pharmaceutical Inc., Amicus Therapeutics Inc., RegenxBio Inc, University of Texas Southwestern Medical Centre, and New York Medical College. In 2023, the highest number of trials were conducted by BioMarin Pharma after adding up all the trial phases.
BD Marketed and Pipeline Drugs Market Analysis by Sponsors, 2023 (%)
Buy Full Report for More Sponsor Insights into the BD Marketed and Pipeline Drugs Market Download A Free Report Sample
Segments Covered in the Report
BD Pipeline Drugs Mechanisms of Action Outlook (Number of Drugs, 2023)
- Enzyme Activators
- Protein and Peptide Activators
- Receptor Agonists
- Biological Factor Replacements
- Protein and Peptide Inhibitors
- Enzyme Inhibitors
- Enzyme Replacement
BD Pipeline Drugs Routes of Administration Outlook (Number of Drugs, 2023)
- Injection
- Oral
- Topical
BD Pipeline Drugs Molecule Types Outlook (Number of Drugs, 2023)
- Biologics
- Small Molecules
- Oligonucleotides
Scope
Components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the BD market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global BD market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Frequently asked questions
-
Which is the leading MoA for BD pipeline drugs?
In 2023, most of the BD pipeline drugs are enzyme activators or protein and peptide activators.
-
Which is the leading RoA for BD pipeline drugs?
In 2023, most of the drugs in the BD pipeline are administered orally.
-
Which is the leading molecule type for BD pipeline drugs?
In 2023, most of the pipeline drugs for BD are small molecules.
-
Who are the top sponsors for BD marketed and pipeline drugs market?
Some of the top sponsors in the BD marketed and pipeline drugs market are BioMarin Pharmaceutical Inc., Amicus Therapeutics Inc., RegenxBio Inc, University of Texas Southwestern Medical Centre, and New York Medical College.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Batten Disease reports



